04 January 2009
New Delhi, India
The programme is aimed at monitoring the drugs which have side–effects and will enable a database to recommend withdrawals of such medicines and amendments in them if needed.
The drugs include rosuvastatin used as lipid lowering cholesterol–control agent, cox–2 inhibitors used as painkillers, phenylpropylamine for nasal decongestant, analgen and phenylbutazone used as painkillers, thioridazine an antipsychotic drug, nimesulide, another pain killer drug, furazolidone antidysentery drug and gatifloxacin, an antibiotic drug.
As part of the programme, side–effects of a drug will be entered in a database called to help in deciding the future course of action on a medicine. “Under this programme any effect on a patient—like death, life–threatening, hospitalisation, disability, congenital anomaly—all reactions suspected to have been caused by new drugs will be keyed into the database. It will be used to determine what action to be taken to improve safe use,” Surinder Singh, drugs controller general, said.
Y K Gupta, head of pharmacology, AIIMS, added that these reports shall also be submitted to the WHO International Drug Monitoring Programme for collaboration on drug safety. AGENCIES
Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ‘Fair dealing’ or ‘Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.
